✦ LIBER ✦

(041) Outcome of the first corticosteroid treatment course in uncomplicated Crohn’s disease: A multicentre study

✍ Scribed by M. Nakmouche; N. Kaddache; A. Balamane; K. Belhocine; L. Kecili; N. Bounab; K. Layaida; L. Gamar; T. Boucekkine

Book ID: 119184148
Publisher: Elsevier
Year: 2009
Tongue: English
Weight: 39 KB
Volume: 10
Category: Article
ISSN: 1687-1979
DOI: 10.1016/j.ajg.2009.07.062

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P392 Outcomes after elective withdrawal

P392 Outcomes after elective withdrawal of anti-TNF therapy in Crohn's disease: a multicentre study

✍ Sebastian, S.; Robinson, K.; Warren, L.; Marsh, A.; Wright, A.; Majeed, F.; Tsai 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 114 KB

Infliximab in the treatment of Crohn's d

Infliximab in the treatment of Crohn's disease: Predictors of response in an Italian multicentric open study

✍ A. Orlando; E. Colombo; A. Kohn; L. Biancone; F. Rizzello; A. Viscido; R. Sosteg 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 73 KB

S2008 Long- Term Outcome of Treatment Wi

S2008 Long- Term Outcome of Treatment With Infliximab in Paediatric Crohn's Disease:a Population-Based Study

✍ Crombé, Valérie; Salleron, Julia; Savoye, Guillaume; Dupas, Jean-Louis; Vernier- 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Intestinal lavage in the treatment of cr

Intestinal lavage in the treatment of crohn's disease: A pilot study

✍ Wellmann, W. ;Schmidt, F. W. 📂 Article 📅 1982 🏛 Springer-Verlag 🌐 English ⚖ 336 KB

Budesonide is less effective than conven

Budesonide is less effective than conventional corticosteroids in the treatment of Crohn's disease. A meta-analysis

✍ C. Papi; L. Gili; R. Luchetti; S. Montanti; M. Koch; L. Capurso 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 166 KB

Long-term outcome of treatment with infl

Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: A population-based study

✍ Valérie Crombé; Julia Salleron; Guillaume Savoye; Jean-Louis Dupas; Gwénola Vern 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 549 KB

Background: We examined short-and long-term benefits and safety of infliximab (IFX) in a population-based cohort of Crohn's disease (CD) patients <17 years old at diagnosis. ## Methods: The following parameters were assessed: short-and long-term efficacy of IFX, impact of drug efficacy, and mode